Enhancing slow-wave sleep via tDCS modulates Alzheimer’s biomarker clearance, pilot study finds
Lead
A small randomized trial from researchers at University Medicine Greifswald in Germany has produced the first human evidence that non-invasive brain stimulation during sleep can alter blood levels of proteins linked to Alzheimer’s disease. The preprint, posted on bioRxiv on June 22, 2026, shows that slow-oscillatory transcranial direct current stimulation (so-tDCS) during NREM sleep increased overnight plasma p-tau181 while shifting relationships between sleep microstructure and amyloid markers.
What they found
Ten healthy older adults (mean age 69 years) completed a randomized, crossover, sham-controlled experiment. Each participant underwent one night of active so-tDCS during NREM sleep and one night of sham stimulation. A subset of seven participants then received five consecutive nights of active so-tDCS to examine longitudinal effects.
Compared with sham, so-tDCS produced small-to-moderate increases in slow oscillation (SO) power and in the strength of SO-spindle coupling, two established markers of sleep microstructure linked to memory consolidation and restorative processes.
The key biomarker result was a significant overnight increase in plasma p-tau181 following active stimulation relative to sham. This increase was strongly and positively associated with the increase in SO power: individuals who showed the largest boost in slow-wave activity also showed the largest rise in p-tau181. The authors interpret this as consistent with enhanced clearance of tau proteins from the brain into the bloodstream via glymphatic pathways, rather than a pathological increase.
The study also revealed a dissociation between two sleep features and different Alzheimer’s-related proteins. SO power was primarily linked to tau dynamics. In contrast, the precise timing of SO-spindle coupling (specifically, a shift of spindles toward the up-state of the slow oscillation) was associated with overnight increases in amyloid-beta 42 (Ab42) and Ab40, as well as longitudinal decreases in Ab42 and the Ab42/Ab40 ratio over five nights of stimulation.
These divergent associations suggest that different components of sleep microstructure may be linked to the clearance of different Alzheimer’s-related proteins, offering more granular targets for intervention.
Why it matters
Sleep disruption and Alzheimer’s disease feed into each other in a well-documented bidirectional cycle. Poor sleep impairs glymphatic clearance (the brain’s waste-removal system that is most active during slow-wave sleep), allowing amyloid and tau aggregates to accumulate, which in turn further disrupts sleep architecture. Breaking this cycle has been a major goal of sleep and neurodegeneration research.
This study is the first to show that electrically enhancing slow-wave sleep in humans can produce measurable changes in blood levels of Alzheimer’s biomarkers. The direction of the effects (increased p-tau181 following stimulation) aligns with the hypothesis that boosting slow-wave activity facilitates the brain-to-blood clearance of tau. If confirmed in larger samples, the approach could open a non-pharmacological route to supporting glymphatic function in older adults at risk for Alzheimer’s disease.
The dissociation between SO power and SO-spindle coupling timing further suggests that sleep microstructure may offer more than one knob to turn. Future interventions might target specific oscillatory features depending on which protein clearance pathway is most relevant.
Limits
As a bioRxiv preprint, this work has not yet undergone peer review. The sample size is small (n=10 for the main crossover comparison, n=7 for the longitudinal extension), which limits statistical power and the generalizability of the findings. The associations between sleep parameters and biomarker changes were correlational and exploratory. Plasma biomarkers, while increasingly used in Alzheimer’s research, are indirect measures of brain clearance; direct confirmation of glymphatic flow changes would require imaging modalities not used in this study. The authors note that the findings should be replicated in larger cohorts before any clinical conclusions can be drawn.
Bottom line
This pilot study provides initial human evidence that enhancing slow-wave sleep via tDCS can modulate blood levels of Alzheimer’s-associated proteins, with distinct sleep features linked to tau versus amyloid dynamics. The findings are exploratory but point toward sleep microstructure as a potential intervention target. Larger, confirmatory studies are needed.
Source
Ladenbauer, J., Schuemann, P., Rizk, Y., Malinowski, R., Dikici, B., Vogelgesang, A., & Floeel, A. (2026). Enhancing slow-wave sleep via non-invasive brain stimulation modulates brain-to-blood clearance of Alzheimer’s disease biomarkers. bioRxiv. DOI: 10.64898/2026.06.22.733841